# ANTARES PHARMA, INC.

ANTARES PHARMA, INC. is a company headquartered in Ewing, NJ, United States.

## Company overview

- **Legal name:** ANTARES PHARMA, INC.
- **Former names in filing history:** ANTARES PHARMA INC (2005-05-04 to 2008-05-15); ANTARES PHARMA INC (2002-05-20 to 2006-01-10); ANTARES PHARMA INC /MN/ (2001-08-14 to 2002-05-14); MEDI JECT CORP /MN/ (1996-08-21 to 2001-03-14)
- **Classification:** Company
- **Industry (SIC):** 3841 — Surgical & Medical Instruments & Apparatus
- **Headquarters:** Ewing, NJ, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001016169

## About

ANTARES PHARMA, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001016169, and its reported industry is Surgical & Medical Instruments & Apparatus. In 10-K filed on 2022-03-03, it reported annual revenue of USD 183,982,000; net income of USD 46,289,000; total assets of USD 257,505,000 for the fiscal period ended 2021-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $184.0M (USD 183,982,000)
- **Net income:** $46.3M (USD 46,289,000)
- **Total assets:** $257.5M (USD 257,505,000)
- **Cash and equivalents:** $65.9M (USD 65,913,000)
- **Operating cash flow:** $36.6M (USD 36,619,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $149.6M (USD 149,599,000)
- **Net income:** $56.2M (USD 56,201,000)
- **Total assets:** $212.5M (USD 212,531,000)
- **Cash and equivalents:** $53.1M (USD 53,137,000)
- **Operating cash flow:** $21.3M (USD 21,320,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $123.9M (USD 123,864,000)
- **Net income:** -$2.0M (USD -2,027,000)
- **Total assets:** $132.8M (USD 132,751,000)
- **Cash and equivalents:** $23.2M (USD 23,201,000)
- **Operating cash flow:** -$10.6M (USD -10,615,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $63.6M (USD 63,554,000)
- **Net income:** -$6.5M (USD -6,515,000)
- **Total assets:** $88.3M (USD 88,277,000)
- **Cash and equivalents:** $27.9M (USD 27,892,000)
- **Operating cash flow:** -$17.3M (USD -17,322,000)

## Recent SEC filings

- Form 8-K — filed 2022-05-24 — period 2022-05-24 — 8-K
- Form 10-Q — filed 2022-05-10 — period 2022-03-31 — 10-Q
- Form SC 13G — filed 2022-05-06
- Form SC 13D — filed 2022-05-02 — SC 13D
- Form 10-K/A — filed 2022-04-29 — period 2021-12-31 — 10-K/A
- Form 8-K — filed 2022-04-13 — period 2022-04-12 — FORM 8-K
- Form 8-K — filed 2022-03-07 — period 2022-03-07 — 8-K
- Form 10-K — filed 2022-03-03 — period 2021-12-31 — 10-K
- Form 8-K — filed 2022-03-03 — period 2022-03-03 — 8-K
- Form SC 13G — filed 2022-02-14 — SC 13G
- Form 8-K — filed 2022-01-11 — period 2022-01-11 — 8-K
- Form 8-K — filed 2021-12-16 — period 2021-12-15 — 8-K

---

Updated: 2026-10-23T20:06:36Z

Canonical page: https://altss.com/profile/antares-pharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology